MDM2 inhibitors for cancer therapy

Trends in Molecular Medicine

Volumn 13, Issue 1, 2007, Pages 23-31

  Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; DOXORUBICIN; ETOPOSIDE; HL 198C; NUTLIN 3; OXINDOLE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; QUILINOL; SPIRO COMPOUND; UNCLASSIFIED DRUG;

CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

BENZODIAZEPINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; SPIRO COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

MURINAE;

EID: 33845901313     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.11.002     Document Type: Review

References (85)

1. Vogelstein B., et al. Surfing the p53 network. Nature 408 (2000) 307-310
2. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
3. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
4. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 10 (2003) 431-442
5. Moll U.M., et al. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17 (2005) 631-636
6. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
7. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
8. Bullock A.N., and Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer 1 (2001) 68-76
9. Fojo T. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist. Updat. 5 (2002) 209-216
10. Lane D.P. Exploiting the p53 pathway for cancer diagnosis and therapy. Br. J. Cancer 80 Suppl 1 (1999) 1-5
11. Fakharzadeh S.S., et al. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics 15 (1993) 283-290
12. Oliner J.D., et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
13. Freedman D.A., et al. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55 (1999) 96-107
14. Momand J., et al. The MDM2 gene amplification database. Nucleic Acids Res. 26 (1998) 3453-3459
15. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13 (2003) 49-58
16. Momand J., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
17. Honda R., et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
18. Haupt Y., et al. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
19. Kubbutat M.H., et al. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
20. Jones S.N., et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 (1995) 206-208
21. Montes de Oca Luna R., et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
22. Leng R.P., et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112 (2003) 779-791
23. Dornan D., et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429 (2004) 86-92
24. Chen D., et al. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
25. Bottger V., et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18 (1999) 189-199
26. Marine J.C., and Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331 (2005) 750-760
27. Parant J., et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29 (2001) 92-95
28. Migliorini D., et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22 (2002) 5527-5538
29. Francoz S., et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3232-3237
30. Xiong S., et al. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3226-3231
31. Marine J.C., et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13 (2006) 927-934
32. Danovi D., et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol. 24 (2004) 5835-5843
33. Bond G.L., et al. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5 (2005) 3-8
34. Vousden K.H., and Prives C. P53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
35. Bottger A., et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7 (1997) 860-869
36. Chene P., et al. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 299 (2000) 245-253
37. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3 (2003) 102-109
38. Klein C., and Vassilev L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91 (2004) 1415-1419
39. Chen L., et al. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 195-200
40. Tortora G., et al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int. J. Cancer 88 (2000) 804-809
41. Zhang R., et al. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr. Cancer Drug Targets 5 (2005) 43-49
42. Zhang Z., et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279 (2004) 16000-16006
43. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2 (2003) 623-629
44. Yang Y., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
45. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (2004) 301-317
46. Fry D.C., and Vassilev L.T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med. 83 (2005) 955-963
47. Kussie P.H., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (1996) 948-953
48. Fotouhi N., and Graves B. Small molecule inhibitors of p53/MDM2 interaction. Curr. Top. Med. Chem. 5 (2005) 159-165
49. Vassilev L.T. p53 Activation by small molecules: application in oncology. J. Med. Chem. 48 (2005) 4491-4499
50. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
51. Tovar C., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1888-1893
52. Grasberger B.L., et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48 (2005) 909-912
53. Leonard K., et al. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorg. Med. Chem. Lett. 16 (2006) 3463-3468
54. Koblish H.K., et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther. 5 (2006) 160-169
55. Parks D.J., et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett. 16 (2006) 3310-3314
56. Issaeva N., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
57. Krajewski M., et al. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11 (2005) 1135-1136
58. Ding K., et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127 (2005) 10130-10131
59. Ding K., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 49 (2006) 3432-3435
60. Lu Y., et al. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J. Med. Chem. 49 (2006) 3759-3762
61. Hollstein M., et al. p53 mutations in human cancers. Science 253 (1991) 49-53
62. Ahrendt S.A., et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7382-7387
63. Poyurovsky M.V., and Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev. 20 (2006) 125-131
64. Michalak E., et al. Death squads enlisted by the tumour suppressor p53. Biochem. Biophys. Res. Commun. 331 (2005) 786-798
65. Satyamoorthy K., et al. No longer a molecular black box - new clues to apoptosis and drug resistance in melanoma. Trends Mol. Med. 7 (2001) 191-194
66. Satyamoorthy K., et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 11 (2000) 467-474
67. Soengas M.S., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409 (2001) 207-211
68. Patton J.T., et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 66 (2006) 3169-3176
69. Gudkov A.V., and Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3 (2003) 117-129
70. Mendrysa S.M., et al. Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23 (2003) 462-472
71. Mendrysa S.M., et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20 (2006) 16-21
72. Vassilev L.T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3 (2004) 419-421
73. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
74. Ljungman M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2 (2000) 208-225
75. Thompson T., et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279 (2004) 53015-53022
76. Stuhmer T., et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106 (2005) 3609-3617
77. Kojima K., et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106 (2005) 3150-3159
78. Coll-Mulet L., et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107 (2006) 4109-4114
79. Secchiero P., et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107 (2006) 4122-4129
80. Brummelkamp T.R., et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2 (2006) 202-206
81. Blagosklonny M.V., and Pardee A.B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61 (2001) 4301-4305
82. Keyomarsi K., and Pardee A.B. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog. Cell Cycle Res. 5 (2003) 527-532
83. Blagosklonny M.V., et al. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J. Clin. Invest. 105 (2000) 533-539
84. Carvajal D., et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 65 (2005) 1918-1924
85. Gudkov A.V., and Komarova E.A. Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun. 331 (2005) 726-736